Business Wire
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
📊
AI Sentiment
Positive
7/10
- Home
- AZN
AZN
AstraZeneca PLC
as of 03-10-2026 3:38pm EST
$195.27
+$0.32
+0.16%
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 285.7B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $61.24 - $212.71 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 10.13% | Revenue Growth (next year): | 6.21% |
| P/E Ratio: | 31.91 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +18.40% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Simply Wall St.
Is AstraZeneca (LSE:AZN) Still Attractive After Recent Share Price Pullback?
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
AstraZeneca Oncology Updates Prompt Fresh Look At Valuation And Growth Potential
📈
AI Sentiment
Highly Positive
8/10
Reuters
Factbox-Global drugmakers rush to boost US presence as tariff threat looms
📈
AI Sentiment
Highly Positive
9/10
Zacks
Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?
📉
AI Sentiment
Negative
2/10
CNW Group
Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1
📈
AI Sentiment
Highly Positive
9/10
Argus Research
Daily Spotlight: A Range of Options Among Sovereign Debt
âž–
AI Sentiment
Neutral
4/10
Compare AZN vs Leading Stocks
See how AZN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.